

# Identification of the control region for tissue-specific imprinting of the stimulatory G protein $\alpha$ -subunit

Jie Liu\*, Min Chen\*, Chuxia Deng<sup>†</sup>, Déborah Bourc'his<sup>‡</sup>, Julie G. Nealon\*<sup>§</sup>, Beth Erlichman\*<sup>¶</sup>, Timothy H. Bestor<sup>‡</sup>, and Lee S. Weinstein\*<sup>||</sup>

\*Metabolic Diseases Branch and <sup>†</sup>Genetics of Development and Disease Branch, National Institute of Diabetes, Digestive, and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892; and <sup>‡</sup>Department of Genetics and Development, Columbia University College of Physicians and Surgeons, New York, NY 10032


Edited by Lutz Birnbaumer, National Institutes of Health, Research Triangle Park, NC, and approved February 25, 2005 (received for review November 5, 2004)

*Gnas* is a complex gene with multiple imprinted promoters. The upstream *Nesp* and *Nespas/Gnasxl* promoters are paternally and maternally methylated, respectively. The downstream promoter for the stimulatory G protein  $\alpha$ -subunit ( $G_{s\alpha}$ ) is unmethylated, although in some tissues (e.g., renal proximal tubules),  $G_{s\alpha}$  is poorly expressed from the paternal allele. Just upstream of the  $G_{s\alpha}$  promoter is a primary imprint mark (1A region) where maternal-specific methylation is established during oogenesis. Pseudohypoparathyroidism type 1B, a disorder of renal parathyroid hormone resistance, is associated with loss of 1A methylation. Analysis of embryos of *Dnmt3L*<sup>-/-</sup> mothers (which cannot methylate maternal imprint marks) showed that *Nesp*, *Nespas/Gnasxl*, and 1A imprinting depend on one or more maternal primary imprint marks. We generated mice with deletion of the 1A differentially methylated region. These mice had normal *Nesp-Nespas/Gnasxl* imprinting, indicating that the *Gnas* locus contains two independent imprinting domains (*Nespas-Nespas/Gnasxl* and 1A- $G_{s\alpha}$ ) controlled by distinct maternal primary imprint marks. Paternal, but not maternal, 1A deletion resulted in  $G_{s\alpha}$  overexpression in proximal tubules and evidence for increased parathyroid hormone sensitivity but had no effect on  $G_{s\alpha}$  expression in other tissues where  $G_{s\alpha}$  is normally not imprinted. The 1A region is a maternal imprint mark that contains one or more methylation-sensitive cis-acting elements that suppress  $G_{s\alpha}$  expression from the paternal allele in a tissue-specific manner.

genomic imprinting | pseudohypoparathyroidism | DNA methylation | guanine nucleotide binding protein

Genomic imprinting is an epigenetic phenomenon involving a small number of genes in which the two parental alleles have distinct epigenetic marks (e.g., DNA methylation and histone modification) that usually lead to allele-specific differences in gene expression (1). These marks are erased within primordial germ cells and reestablished during gametogenesis. The most well established examples of primary imprint marks are regions in which DNA methylation is established on one parental allele during gametogenesis and maintained throughout development. These primary imprint marks can then produce other allele-specific epigenetic changes within neighboring regions to generate large domains including multiple imprinted genes.

*Gnas* is a complex imprinted locus on mouse chromosome 2 that generates multiple gene products by the use of alternative promoters and first exons that splice onto a common set of downstream exons (exons 2–12, Fig. 1A) (2). The human ortholog *GNAS* at 20q13 has a similar overall structure and imprinting pattern. The major *Gnas* product, the stimulatory G protein  $\alpha$ -subunit ( $G_{s\alpha}$ ), which mediates receptor-stimulated cAMP production, is generated from the most downstream promoter and first exon. Promoters for the chromogranin-like protein NESP55 (*Nesp*) and  $G_{s\alpha}$  isoform XL $\alpha$ s (*Gnasxl*) are located 45 and 30 kb upstream of  $G_{s\alpha}$  exon 1, respectively (3). *Nesp* and *Gnasxl* are oppositely imprinted; the *Nesp* promoter is



**Fig. 1.** *Gnas* methylation analysis in embryos derived from *Dnmt3L*<sup>-/-</sup> mothers. (A) The maternal (Mat) and paternal (Pat) alleles of *Gnas* are depicted with alternative first exons NESP (*Nesp*), XL $\alpha$ s (*Gnasxl*), 1A, and  $G_{s\alpha}$  splicing to common exon 2 (exons 3–12 are not shown). DNA methylation (Meth) and splicing patterns are shown above and below each image, respectively. Horizontal arrows indicate active promoters and the direction of transcription. The paternal  $G_{s\alpha}$  promoter is suppressed in some tissues (gray arrow). The *Gnasxl* promoter also generates paternal-specific antisense transcripts (*Nespas*), whose first exon (AS) is shown. The diagram is not drawn to scale. (B) Bisulfite-modified genomic sequencing of +/+ embryos (8.5 days postcoitus) and embryos derived from *Dnmt3L*<sup>-/-</sup> mothers (*Dnmt3L*) within the *Nesp*, *Nespas*, *Gnasxl*, and 1A DMRs, respectively (black boxes indicate examined regions). Asterisks indicate positions of CpG cytosines in *Nesp*.

DNA methylated on the paternal allele and transcriptionally active on the maternal allele, whereas *Gnasxl* is methylated on the maternal allele and active on the paternal allele (4, 5). *Nesp* is not a primary imprinting center because its imprinting is not established until after implantation (6). Paternal-specific antisense transcripts (*Nespas*) generated from the *Gnasxl* promoter region may be important for *Nesp* imprinting (7, 8).

This paper was submitted directly (Track II) to the PNAS office.


Abbreviations:  $G_{s\alpha}$ , stimulatory G protein  $\alpha$ -subunit; PHP1A/B, pseudohypoparathyroidism types 1A and 1B; PTH, parathyroid hormone; DMR, differentially methylated region.

<sup>§</sup>Present address: Bullis School, Potomac, MD 20854.

<sup>¶</sup>Present address: University of Texas, Austin, TX 78712.

<sup>||</sup>To whom correspondence should be addressed. E-mail: leew@amb.niddk.nih.gov.

© 2005 by The National Academy of Sciences of the USA



**Fig. 2.** Generation of  $1A^{-}$  mice. (A) The upstream portion of the wild-type *Gnas* allele including exons 1A, 1, and 2 is shown at the top. The 1A DMR is shown by a hatched rectangle, and positions of probes A and B for Southern blot analysis are shown above. The scale at the top is given in kb, with 0 kb being the  $G_{s\alpha}$  translational start site. Upstream *SacI* and downstream *BamHI*–*SstI* fragments were inserted into pLoxpneo to generate the targeting construct. Neo1A<sup>-</sup> and 1A<sup>-</sup> alleles are shown below. E, *EcoRI*; S, *SacI*; Bg, *BglII*; B, *BamHI*; Ss, *SstI*; H, *HpaI*; Neo, neomycin resistance gene; TK, thymidine kinase gene; triangle, loxP site. (B) Southern blot analysis of DNA from ES cells or mice after *EcoRI* digestion and hybridization with probe A. Genotypes are indicated above each lane (parental assignment unknown). *EcoRI* fragments derived from +, Neo1A<sup>-</sup>, and 1A<sup>-</sup> alleles are shown in A. (C) Southern blot analysis of liver DNA from +/+, 1A<sup>+p/-</sup>, and 1A<sup>m/-+</sup> mice performed by using a *BglII* (Bg)–*BamHI* (B) probe within the 1A DMR after digestion with enzymes indicated above each lane (M, *MspI*; Hp, *HpaII*). A restriction map is shown, with M/Hp sites indicated as vertical lines and lengths of digestion products (in bp) shown above.

$G_{s\alpha}$  is imprinted in a tissue-specific manner, being expressed primarily from the maternal allele in renal proximal tubules, pituitary, thyroid, and ovaries but biallelically expressed in most other tissues (9–13). (Throughout this article, we use the term  $G_{s\alpha}$  imprinting to refer to allele-specific differences in  $G_{s\alpha}$  expression in specific tissues, not the underlying epigenetic marks, which are presumably not tissue-specific.)  $G_{s\alpha}$  imprinting is not associated with DNA methylation of its promoter but is associated with allele-specific differences in histone methylation (6, 14). Heterozygous  $G_{s\alpha}$ -inactivating mutations in Albright hereditary osteodystrophy also lead to parathyroid hormone (PTH), TSH, and gonadotropin resistance (pseudohypoparathyroidism type 1A, PHP1A) when present on the maternal allele (2) because of the loss of  $G_{s\alpha}$  expression from the active maternal allele in hormone target tissues.

Just upstream of the  $G_{s\alpha}$  promoter is a differentially methylated region (DMR) that is methylated on the maternal allele and contains a promoter and first exon (exon 1A), which generates paternal-specific mRNAs of unknown function (6, 15) (Fig. 1A). This DMR is a primary imprint mark, because its methylation is established during oogenesis and maintained throughout development (6). This region also has allele-specific differences in histone modifications (14). In PHP1B, in which patients develop renal PTH resistance but not Albright hereditary osteodystrophy, maternal imprinting (methylation) of the 1A DMR is lost (15). We have suggested that the 1A DMR has cis-acting negative regulatory elements (e.g., silencers or insulators) for the  $G_{s\alpha}$  promoter that are both methylation-sensitive (and, hence, suppress  $G_{s\alpha}$  only on the paternal allele) and tissue-specific (perhaps because of tissue-specific expression of trans-acting factors) (2, 15). This model predicts that loss of maternal 1A methylation in PHP1B leads to biallelic loss of  $G_{s\alpha}$  expression in renal proximal tubules and renal PTH resistance, but it has little

effect in most other tissues where normally the cis-acting elements do not affect  $G_{s\alpha}$  promoter activity.

In this study, we directly tested the role of the 1A DMR on *Gnas* and tissue-specific  $G_{s\alpha}$  imprinting by generating mice with deletion of the 1A DMR. Studies in these mice, as well as in mouse embryos that are unable to establish maternal primary methylation imprints, show that *Gnas* consists of two independent imprinting domains and that tissue-specific  $G_{s\alpha}$  imprinting is controlled by elements with the 1A DMR.

## Materials and Methods

**Generation of Targeting Construct.** A clone containing *Gnas* exons 1 and 1A was isolated from a 129SvEv mouse genomic DNA library (Stratagene). A 4.2-kb *BamHI*–*SspI* fragment (–1,601/+2,602; base pair position relative to  $G_{s\alpha}$  translational start site) was subcloned into the *BamHI* and *EcoRI* sites downstream of the loxP–neomycin resistance gene (Neo)–loxP cassette within pLoxpneo (16) (Fig. 2A). Next, a 5.3-kb *SacI* fragment (–11,600/–6,267) was inserted into a *HpaI* site located upstream of the loxP–Neo cassette, and the targeting construct was isolated after *NotI* digestion.

**Generation of 1A<sup>-</sup> Mice.** TC1 ES cells (17) were transfected with the targeting construct and selected with G418 and FIAU. Doubly resistant ES colonies were analyzed by Southern blot analysis for homologous recombination. ES cells heterozygous for the targeted mutation (Neo1A<sup>-</sup>, Fig. 2A) were microinjected into C57/B6 blastocysts, and resulting male chimeras were mated with NIH Black Swiss females (Taconic Farms) to achieve germline transmission. Neo1A<sup>-</sup> mice were mated with *EIIa* promoter-cre mice (18) to excise Neo (1A<sup>-</sup> allele, Fig. 2A; referred to as  $\Delta^{-6267/-1601}$  in ref. 14). Mice were maintained on standard chow diet (National Institutes of Health, Bethesda) with 12:12-h light/dark cycle. E1<sup>-</sup> mice with deletion of adjoin-

ing downstream sequence from  $-1,601$  to  $+419$  (referred to as  $\Delta^{-1601/+419}$  in ref. 14) have been described (M.C., unpublished data). Embryonic day 8.5 embryos were derived from *Dnmt3L*<sup>-/-</sup> mothers as described (19). Mouse studies were approved by the National Institute of Diabetes and Digestive and Kidney Diseases Animal Care and Use Committee.

**Genotyping.** Genomic DNA was isolated from ES cells or tissues by using the Genomic DNA buffer set (Qiagen, Valencia, CA). Samples were digested with *Bgl*II and hybridized with a labeled 1.3-kb *Ssp*I–*Not*I genomic fragment (probe B, Fig. 2A) or were digested with *Eco*RI and hybridized with an 878-bp *Kpn*I–*Sac*I genomic fragment (probe A, Fig. 2A and B). Subsequent genotyping was performed by PCR of mouse tail DNA using the following cycling profile: 94°C for 5 min, followed by 35 cycles of 94°C for 45 s, 64°C for 45 s, and 72°C for 60 s. The following primers were used: 5'-GCCGATTTTTTGGCGGTC-CCCTTC-3' and 5'-GCTTCTTCCATCTTCTTGGC-3', which generates a 530-bp band from the wild-type allele; and 5'-GATAGCCTTTCACCCAGTAG-3' and 5'-TTTGGCGGCGGCACATCGCG-3', which generates a 380-bp band from the 1A<sup>-</sup> allele.

**Southern Blot Analysis with Methylation-Sensitive Restriction Enzymes.** DNA samples (20  $\mu$ g) were digested with the indicated restriction enzymes (New England Biolabs). Genomic probes were generated by PCR using the following sets of upstream and downstream primers: *Nesp* upstream region, 5'-TAGCCATGATGCTCTTGCTGAC-3' and 5'-GGGTGAGATACAGTAGGTGC-3'; *Gnasxl* upstream region, 5'-GACGGAGC-GAACGTCCTAC-3' and 5'-GAGAAGTGAGGATAGCTTAGC-3'; and *Nespas/Gnasxl* promoter region, 5'-GTTGTAGTCAGGGCTTGCTCTG-3' and 5'-TGCAGCTCTTTGTGCACAGC-3'.

**Bisulfite-Modified Genomic Sequencing.** Bisulfite-modified genomic sequencing was performed on genomic DNA samples as described (6). Primers for the 1A DMR, *Nesp*, and *Gnasxl* first exon have been reported (6). For the *Nespas/Gnasxl* promoter region, the following initial upstream and downstream primers were used, respectively: 5'-GTAATTTTATAGGGTTT-TATTG-3' and 5'-ATCCATTCTCTTAAATACTCACC-3'; and the following nested upstream and downstream primers were used, respectively: 5'-GAGAGGATTAGTGAGG-TATTTTT-3' and 5'-ACTCACCTCTAACTCTACAAA-AAAT-3'. Amplified fragments were gel-purified and sequenced with a nested primer by using the Thermo Sequenase kit (United States Biochemical).

**Immunoblot Analysis.** Proximal tubules were isolated from renal cortex as described (10). Tissues were homogenized in ice-cold lysis buffer (50 mM Tris-HCl/1% Nonidet P-40/0.5% Na deoxycholate/150 mM NaCl, 1 mM PMSF/1 mM Na<sub>3</sub>VO<sub>4</sub>/1 mM NaF, containing protease inhibitor mixture) (Roche) with a Teflon pestle (3 ml of buffer per g of tissue) and incubated for 60 min at 4°C. Homogenates were centrifuged at 4°C in a microcentrifuge for 10 min at 16,000  $\times$  g, and supernatants were used for immunoblotting. Protein concentrations were determined by the dye method (Bio-Rad). Immunoblotting was performed as described (10, 20). To normalize for loading, the relative amounts of protein in each sample were determined by Simply Blue SafeStain (Invitrogen) staining and quantified with ALPHAEASE FC software (Alpha Innotech, San Leandro, CA).

**Real-Time Quantitative RT-PCR.** Total RNA was isolated by using TRIzol reagent and treated with DNase I (Invitrogen). Quantitative RT-PCR was performed on an MxP3000 real-time PCR system (Stratagene) by using SYBR Green PCR master mix and

RT-PCR kit (Applied Biosystems). The PCR cycling profile was 95°C for 10 min, followed by 40 amplification cycles of 95°C for 30 s, 58°C for 60 s, and 72°C for 30 s, and a final cycle of 95°C for 60 s and 55°C for 30 s to generate dissociation curves. A standard curve was generated in each experiment and used to determine the relative abundance of *G<sub>s</sub>* $\alpha$  mRNA in each sample. *G<sub>s</sub>* $\alpha$  expression was normalized to  $\beta$ -actin mRNA levels, which were determined in a similar fashion. Standard curves demonstrated efficiencies of >90% in all experiments. Generation of multiple RT-PCR products was ruled out by both dissociation curves and acrylamide gel electrophoresis. The following upstream and downstream primers were used: *G<sub>s</sub>* $\alpha$ , 5'-CTCCGT-TAAACCCATTAACATGCA-3' and 5'-ACAAGCAGGTC-TACCGGGCC-3'; and  $\beta$ -actin, 5'-GACCTCTATGCCAA-CACAGT-3' and 5'-TAGGAGCCAGAGCAGTAATC-3'. Nontemplate controls were included to rule out nonspecific amplification. *Nesp* and *Gnasxl* transcripts were amplified by using the upstream primers 5'-CACTAATGGGTGACTC-CGTCCA-3' and 5'-GGACTACATGTGTACACACCG-3', respectively, and the same downstream primer as described for *G<sub>s</sub>* $\alpha$ .


**Serum Chemistries.** Serum calcium, albumin, and phosphorus were measured by colorimetric assays (Stanbio, Boeme, TX). Serum PTH was measured by using a rat PTH immunoradiometric assay (Immutopics, San Clemente, CA).

## Results

### *Gnas* Imprinting Depends on Maternal Primary Methylation Imprint

**Marks.** To test the role of maternal primary imprint marks in *Gnas* imprinting, we examined methylation of *Gnas* DMRs in embryos derived from *Dnmt3L*<sup>-/-</sup> mothers (Fig. 1B). *Dnmt3L*, although it is not a DNA methylase, has sequence similarity to active DNA methyltransferases of the *Dnmt3* family. Heterozygous embryos derived from *Dnmt3L*<sup>-/-</sup> mothers specifically fail to establish methylation at maternal primary imprint marks during oogenesis (19). *Gnas* methylation was determined by bisulfite-modified genomic sequencing, a method by which DNA is chemically modified so that unmethylated cytosines are converted to uracil before PCR amplification and direct sequencing. In the final sequence, methylated cytosines remain as cytosines, whereas unmethylated cytosines are converted to thymines. In +/+ embryos CpG cytosines were partially converted to thymines at all *Gnas* DMRs, consistent with the presence of one methylated and one unmethylated allele. In embryos from *Dnmt3L*<sup>-/-</sup> mothers, all cytosines within the *Nespas/Gnasxl* promoter, a region within the same DMR located just downstream of the *XLas* first exon, and 1A DMR were fully converted to thymidine, consistent with both parental alleles being unmethylated (the paternal epigenotype). In contrast, there was no CpG cytosine-to-thymidine conversion within *Nesp*, consistent with both alleles being methylated (the paternal epigenotype). Consistent with these methylation changes, quantitative real-time PCR experiments showed these embryos to have undetectable levels of *Nesp* mRNA and a 2.3-fold increase in the level of *Gnasxl* mRNA (data not shown). Therefore, embryos from *Dnmt3L*<sup>-/-</sup> mothers have a paternal epigenotype in both alleles at all *Gnas* DMRs, indicating that *Gnas* imprinting is determined by one or more maternal primary imprint marks. The findings at *Nesp* are consistent with prior results showing that *Nesp* methylation is not established until after implantation development and, therefore, depends on a primary imprint mark within another *Gnas* region (6).


**Generation of Mice with a 1A DMR Deletion.** The 1A DMR has been shown to be a maternal primary imprint mark (6). To determine its role in *Gnas* imprinting, we generated mice with a 1A DMR deletion by targeted mutagenesis (Fig. 2A), in which the region



**Fig. 3.** Effect of 1A deletion on *Nesp* and *Nespas/Gnasxl* methylation. (A) A restriction map of a 9,628-bp *Hind*III (H) fragment including XLaS exon 1 is shown, with *Msp*I (M)/*Hpa*II (Hp) sites indicated by vertical lines. The size of restriction fragments in bp is shown at the top, and the position of the hybridization probe is shown at the bottom. Lower shows Southern blot analysis of liver DNA from +/+, 1A<sup>+/p-</sup>, and 1A<sup>m-/+</sup> mice after digestion with enzymes indicated above each lane. (B) Southern blot analysis of a 3,415-bp *Sac*I (S) fragment including the *Nespas* first exon (AS) and promoter region. (C) Southern blot analysis of a 4,600-bp *Hind*III fragment from the *Nesp* region. In each image, the fragments derived from the methylated and unmethylated alleles are designated as M and U, respectively.

from -6,267 to -1,601 (base pair positions relative to the  $G_{S\alpha}$  translational start site) was replaced by a single loxP site (1A<sup>-</sup> allele). Correct gene targeting, germline transmission, and generation of the 1A<sup>-</sup> allele were confirmed by Southern blot analysis using internal probe A (Fig. 2A and B) and 3' probe B (Fig. 2A and data not shown).

Homozygous 1A<sup>-/-</sup> mice or mice heterozygous for 1A<sup>-</sup> on the maternal (1A<sup>m-/+</sup>) or paternal (1A<sup>+p-</sup>) allele had no obvious phenotype. To confirm that the deletion did not affect 1A imprinting in the opposite allele, liver DNA was subjected to Southern blot analysis with methylation-sensitive restriction enzymes and hybridized to a 1,900-bp *Bgl*II-*Bam*HI genomic probe within the 1A DMR (Fig. 2C). *Msp*I, which is insensitive to CpG methylation at *Msp*I/*Hpa*II sites, completely digested all samples. In +/+ samples, *Hpa*II, which digests the same sites only when they are unmethylated, generated both the undigested 1,900-bp band and smaller digestion products, consistent with the presence of a methylated maternal and an unmethylated paternal allele (6). *Hpa*II digestion of 1A<sup>+p-</sup> samples produced



**Fig. 4.** Paternal 1A deletion reverses  $G_{S\alpha}$  imprinting and the E1<sup>m-/+</sup> neonatal phenotype. (A)  $G_{S\alpha}$  mRNA expression in liver, renal inner medulla, and renal proximal tubules of 1A<sup>m-/+</sup> and 1A<sup>+p-</sup> mice relative to paired +/+ littermates ( $n = 5$  pairs for all groups, except  $n = 4$  for 1A<sup>m-/+</sup> inner medulla). (B) Relative  $G_{S\alpha}$  protein expression in same tissues. ( $n = 5$  pairs for inner medulla and proximal tubules,  $n = 4$  for 1A<sup>m-/+</sup> liver, and  $n = 3$  for 1A<sup>+p-</sup> liver). Results are mean  $\pm$  SEM. \* $P < 0.05$  vs. 100% by  $t$  test. (C) Representative E1<sup>m-/+</sup> (Left), E1<sup>m-/+</sup>:1A<sup>+p-</sup> (Middle), and 1A<sup>+p-</sup> (Right) neonates are shown.

only the undigested band, consistent with deletion of the unmethylated paternal 1A DMR and normal maternal 1A methylation, whereas 1A<sup>m-/+</sup> samples showed only the digested bands, consistent with deletion of the methylated maternal 1A DMR and no methylation of the remaining paternal allele. Therefore, heterozygous 1A deletion does not have a transacting effect on the imprinting status of opposite allele. Similar results were obtained with spleen, lung, and kidney DNA (data not shown).

The 1A deletion extends beyond the 5' end of the DMR, because the most upstream differentially *Hpa*II site is at -2,754 (data not shown). However, the 1A deletion does not remove the 3' end of the DMR, because we have shown that differential methylation extends a further  $\approx 600$  bp downstream of the 1A deletion (6). Southern blot analysis showed that 1A deletion had little effect on methylation of the remaining  $\approx 600$ -bp downstream region. Conversely, removal of this  $\approx 600$ -bp downstream region in E1<sup>-</sup> mice with a -1,601/+419 deletion had no effect on methylation of the major upstream portion of the DMR removed in the 1A deletion (Fig. 6, which is published as supporting information on the PNAS web site). Whether this result indicates that the cis elements required for 1A DMR methylation lie outside of the DMR is unknown.

**The 1A Deletion Has No Effect on *Nesp* or *Nespas/Gnasxl* Imprinting.** To determine whether *Nesp* and *Nespas-Gnasxl* imprinting depend on the 1A DMR, we performed Southern blot analysis on liver DNA digested with *Msp*I or *Hpa*II and hybridized with *Nesp*-, *Nespas/Gnasxl*-, and *Gnasxl* first exon-specific genomic probes (Fig. 3). *Msp*I and *Hpa*II digestion showed similar results



*Nesp* or *Nespas/Gnasxl* imprinting, showing that imprinting of these latter regions does not require the 1A DMR. Similar findings were observed in another 1A DMR-deletion mouse model (26). That *Nesp-Nespas/Gnasxl* imprints independently of the 1A DMR is further supported by the fact that in many PHP1B patients 1A DMR imprinting is lost without any effect on imprinting of the upstream regions and that 1A DMR, but not *Nesp-Nespas/Gnasxl* imprinting, appears to depend on a cis-acting element within the closely linked *STX16* gene (27). Methylation studies suggest the presence of a second maternal primary imprint mark within the *Nespas/Gnasxl* promoter (28). A likely scenario is that methylation is first established within this promoter and then spreads into the *Gnasxl* first exon. *Nesp* imprinting is established later in development either by the action of paternal antisense *Nespas* transcripts (29) or other mechanisms (30, 31).

Tissue-specific  $G_{s\alpha}$  imprinting occurs even though its promoter is unmethylated and has histone modifications consistent with open chromatin on both parental alleles (6, 14). Loss of maternal 1A methylation in PHP1B (15) strongly suggests that the 1A DMR controls  $G_{s\alpha}$  imprinting. Tissue-specific  $G_{s\alpha}$  imprinting is not determined by exon 1A promoter activity or by its mRNA transcripts, as exon 1A- and  $G_{s\alpha}$ -specific mRNAs have a similar tissue distribution pattern (6). It is more likely that the 1A DMR harbors cis-acting regulatory elements that are both tissue-specific and methylation-sensitive (Fig. 5). In the model shown in Fig. 5, the 1A DMR contains a silencer that in proximal tubules binds a tissue-specific repressor and inhibits  $G_{s\alpha}$  expression on the paternal allele. DNA methylation on the maternal allele blocks repressor binding, allowing  $G_{s\alpha}$  to be expressed from this allele. In most other tissues, the repressor is not expressed, and therefore,  $G_{s\alpha}$  is expressed biallelically. In PHP1B, loss of maternal 1A DMR methylation allows the

repressor to bind to both alleles in proximal tubules, leading to  $G_{s\alpha}$  deficiency and PTH resistance. In most other tissues, the repressor is absent, and therefore,  $G_{s\alpha}$  expression is unaffected. As predicted,  $1A^{m-/+}$  mice had no changes in  $G_{s\alpha}$  expression because the silencer is inactive on the maternal allele. In contrast, paternal 1A deletion resulted in  $G_{s\alpha}$  overexpression in proximal tubules but not in other tissues where normally  $G_{s\alpha}$  is biallelically expressed, consistent with deletion of a tissue-specific silencer or other negative regulatory element. Our results directly confirm that the 1A DMR controls tissue-specific  $G_{s\alpha}$  imprinting.

The exact nature of the putative regulatory element within the 1A DMR is unknown. Although methylation-sensitive insulators are important control elements in other imprinted genes (30–32), they are not tissue-specific. Tissue-specific silencers are a strong candidate, because they have been identified in other imprinted genes, including *Igf2* and *Igf2r* (33). Another recent 1A DMR knockout model also provides evidence that this region controls tissue-specific  $G_{s\alpha}$  imprinting (26). Based on the minimal overlap between the two deletions, the elements that regulate  $G_{s\alpha}$  imprinting lie within a 2-kb region (–1.6 to –3.6 kb upstream of the  $G_{s\alpha}$  coding region).

Although heterotrimeric G proteins are not generally considered to be rate-limiting signaling components,  $G_{s\alpha}$  expression and PTH signaling were similarly reduced in proximal tubules by  $\approx 70\%$  in mice with a maternal *Gnas* mutation (10), suggesting that  $G_{s\alpha}$  is rate-limiting for PTH action in this tissue. Consistent with  $G_{s\alpha}$  being rate-limiting, a modest increase in  $G_{s\alpha}$  expression in proximal tubules of  $1A^{+/p-}$  mice had a significant effect on circulating PTH levels consistent with increased PTH signaling.  $G_{s\alpha}$  may be rate-limiting because it is poorly expressed in these cells (10).  $1A^{+/p-}$  mice will be useful to further examine PTH- $G_{s\alpha}$  signaling in proximal tubules.

- Reik, W. & Walter, J. (2001) *Nat. Rev. Genet.* **2**, 21–32.
- Weinstein, L. S., Yu, S., Warner, D. R. & Liu, J. (2001) *Endocr. Rev.* **22**, 675–705.
- Kelsey, G., Bodle, D., Miller, H. J., Beechey, C. V., Coombes, C., Peters, J. & Williamson, C. M. (1999) *Genomics* **62**, 129–138.
- Peters, J., Wroe, S. F., Wells, C. A., Miller, H. J., Bodle, D., Beechey, C. V., Williamson, C. M. & Kelsey, G. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 3830–3835.
- Hayward, B. E., Moran, V., Strain, L. & Bonthron, D. T. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 15475–15480.
- Liu, J., Yu, S., Litman, D., Chen, W. & Weinstein, L. S. (2000) *Mol. Cell. Biol.* **20**, 5808–5817.
- Wroe, S. F., Kelsey, G., Skinner, J. A., Bodle, D., Ball, S. T., Beechey, C. V., Peters, J. & Williamson, C. M. (2000) *Proc. Natl. Acad. Sci. USA* **97**, 3342–3346.
- Hayward, B. E. & Bonthron, D. T. (2000) *Hum. Mol. Genet.* **9**, 835–841.
- Liu, J., Erlichman, B. & Weinstein, L. S. (2003) *J. Clin. Endocrinol. Metab.* **88**, 4336–4341.
- Yu, S., Yu, D., Lee, E., Eckhaus, M., Lee, R., Corria, Z., Accili, D., Westphal, H. & Weinstein, L. S. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 8715–8720.
- Mantovani, G., Ballare, E., Giammona, E., Beck-Peccoz, P. & Spada, A. (2002) *J. Clin. Endocrinol. Metab.* **87**, 4736–4740.
- Hayward, B. E., Barlier, A., Korbonits, M., Grossman, A. B., Jacquet, P., Enjalbert, A. & Bonthron, D. T. (2001) *J. Clin. Invest.* **107**, R31–R36.
- Germain-Lee, E. L., Ding, C.-L., Deng, Z., Crane, J. L., Saji, M., Ringel, M. D. & Levine, M. A. (2002) *Biochem. Biophys. Res. Commun.* **296**, 67–72.
- Sakamoto, A., Liu, J., Greene, A., Chen, M. & Weinstein, L. S. (2004) *Hum. Mol. Genet.* **15**, 819–828.
- Liu, J., Litman, D., Rosenberg, M. J., Yu, S., Biesecker, L. G. & Weinstein, L. S. (2000) *J. Clin. Invest.* **106**, 1167–1174.
- Yang, X., Li, C., Xu, X. & Deng, C. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 3667–3672.
- Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A. & Leder, P. (1996) *Cell* **84**, 911–921.
- Xu, X., Li, C., Garrett-Beal, L., Larson, D., Wynshaw-Boris, A. & Deng, C. X. (2001) *Genesis* **30**, 1–6.
- Bourc'his, D., Xu, G., Lin, C., Bollman, B. & Bestor, T. H. (2001) *Science* **294**, 2536–2539.
- Simonds, W. F., Goldsmith, P. K., Woodard, C. J., Unson, C. G. & Spiegel, A. M. (1989) *FEBS Lett.* **249**, 189–194.
- Williamson, C. M., Beechey, C. V., Papworth, D., Wroe, S. F., Wells, C. A., Cobb, L. & Peters, J. (1998) *Genet. Res.* **72**, 255–265.
- Skinner, J. A., Cattanach, B. M. & Peters, J. (2002) *Genomics* **80**, 373–375.
- Judson, H., Hayward, B. E., Sheridan, E. & Bonthron, D. T. (2002) *Nature* **416**, 539–542.
- Hayward, B. E., De Vos, M., Judon, H., Hodge, D., Huntriss, J., Picton, H. M., Sheridan, E. & Bonthron, D. T. (2002) *BMC Genet.* **4**, 2.
- Liu, J., Nealon, J. G. & Weinstein, L. S. (2005) *Hum. Mol. Genet.* **14**, 95–102.
- Williamson, C. M., Ball, S. T., Nottingham, W. T., Skinner, J. A., Plagge, A., Turner, M. D., Powles, N., Hough, T., Papworth, D., Fraser, W. D., et al. (2004) *Nat. Genet.* **36**, 894–899.
- Bastepe, M., Frohlich, L. F., Hendy, G. N., Indridason, O. S., Josse, R. G., Koshiyama, H., Korkko, J., Nakamoto, J. M., Rosenbloom, A. L., Slyper, A. H., et al. (2003) *J. Clin. Invest.* **112**, 1255–1263.
- Coombes, C., Arnaud, P., Gordon, E., Dean, W., Coar, E. A., Williamson, C. M., Feil, R., Peters, J. & Kelsey, G. (2003) *Mol. Cell. Biol.* **23**, 5475–5488.
- Wutz, A. & Barlow, D. P. (1998) *Nature* **389**, 745–749.
- Bell, A. C. & Felsenfeld, G. (2000) *Nature* **405**, 482–485.
- Hark, A. T., Schoenherr, C. J., Katz, D. J., Ingram, R. S., LeVorse, J. M. & Tilghman, S. M. (2000) *Nature* **405**, 486–489.
- Chao, W., Huynh, K. D., Spencer, R. J., Davidow, L. S. & Lee, J. T. (2002) *Science* **295**, 345–347.
- Ferguson-Smith, A. C. (2000) *Curr. Biol.* **10**, R872–R875.